Haldimann B, Healy M, Jelliffe R, Goldstein D A, Pattabhiraman R, Massry S G
J Clin Endocrinol Metab. 1980 Mar;50(3):470-4. doi: 10.1210/jcem-50-3-470.
Patients with the nephrotic syndrome have low blood levels of 25-hydroxyvitamin D3 (25OHD3) due to urinary losses of the sterol. It is not known whether supplementation of this metabolite could raise its blood levels in these patients. The changes in the plasma levels of 25OHD3 and its kinetic behavior were studied after an oral dose of the sterol (200 microgram) in patients with the nephrotic syndrome in an effort to evaluate the usefulness of oral therapy to achieve and maintain normal blood levels of 25OHD3. Normal subjects served as controls. The results showed that intestinal absorption of 25OHD3 is significantly delayed and its elimination rate is significantly enhanced in patients with the nephrotic syndrome compared to control subjects. Despite these abnormalities, the plasma levels of 25OHD3 were within normal values even 48 h after the ingestion of the sterol. These data indicate that oral therapy with 25OHD3 given in proper doses is adequate to maintain normal blood levels of the sterol in patients with the nephrotic syndrome. Therefore, a therapeutic approach could be designed to manage the target organ disease due to 25OHD3 deficiency seen in these patients.
肾病综合征患者由于固醇类物质经尿液丢失，其血液中25-羟基维生素D3（25OHD3）水平较低。尚不清楚补充这种代谢产物是否能提高这些患者血液中的该物质水平。为评估口服疗法实现并维持25OHD3正常血液水平的有效性，对肾病综合征患者口服一定剂量的固醇类物质（200微克）后，研究了其血浆中25OHD3水平的变化及其动力学行为。正常受试者作为对照。结果显示，与对照受试者相比，肾病综合征患者中25OHD3的肠道吸收显著延迟，其消除速率显著加快。尽管存在这些异常情况，但即使在摄入固醇类物质48小时后，血浆中25OHD3水平仍在正常范围内。这些数据表明，适当剂量的25OHD3口服疗法足以维持肾病综合征患者血液中固醇类物质的正常水平。因此，可以设计一种治疗方法来处理这些患者中因25OHD3缺乏而导致的靶器官疾病。
